[{"id":"8d2bda38-b412-44d9-af69-1874736fb5f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03455270","created_at":"2021-01-17T17:27:43.712Z","updated_at":"2024-07-02T16:35:59.084Z","phase":"Phase 1","brief_title":"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer","source_id_and_acronym":"NCT03455270","lead_sponsor":"G1 Therapeutics, Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • rintodestrant (G1T48)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 05/09/2018","start_date":" 05/09/2018","primary_txt":" Primary completion: 09/29/2022","primary_completion_date":" 09/29/2022","study_txt":" Completion: 09/29/2022","study_completion_date":" 09/29/2022","last_update_posted":"2022-12-15"}]